EcoDrugPlus

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSORLG00000017331
Gene Symbol: KCNK2
3 Cross references
213 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSORLG00000026805
Gene Symbol: KCNA5
4 Cross references
169 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSORLG00000005848
Gene Symbol: KCND3
4 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSORLG00000023740
Gene Symbol: LOC101159502
4 Cross references
192 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSORLG00000028279
Gene Symbol: KCNQ2
3 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSORLG00000006562
Gene Symbol: KCNQ3
4 Cross references
191 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSORLG00000002279
Gene Symbol: KCNQ5
4 Cross references
196 Possible Orthologues:

Potassium Voltage-Gated Channel, Kqt-Like Subfamily, Member 2a

Ensembl ID : ENSORLG00000000854
Gene Symbol: KCNQ2A
1 Cross references
185 Possible Orthologues:

Potassium Voltage-Gated Channel, Subfamily H (Eag-Related), Member 2b

Ensembl ID : ENSORLG00000004137
Gene Symbol: KCNH2B
3 Cross references
185 Possible Orthologues:

Potassium/sodium Hyperpolarization-Activated Cyclic Nucleotide-Gated Channel 3

Ensembl ID : ENSORLG00000029987
Gene Symbol: LOC101159259
3 Cross references
212 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSORLG00000022179
Gene Symbol: PSEN1
4 Cross references
200 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSORLG00000020169
Gene Symbol: PSEN2
4 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).